One of the most important insights in pharmacy benefits today may be this: Prescription affordability is not binary. It’s highly elastic across a surprisingly narrow pricing range. And the behavioral implications are massive. At very low out-of-pocket costs (roughly <$10–15): Most members simply fill the prescription and move on. -There’s little friction. -Little attention. -Little behavior change. But somewhere in the ~$15–30 range, something important happens: Members begin noticing cost. -They begin evaluating tradeoffs. -They become highly influenceable. This may actually be the highest-leverage zone for pharmacy navigation. Not because costs are catastrophic…but because members are still willing to engage before frustration becomes abandonment. Then comes the ~$35–75 range: This is where affordability stress starts driving unstable behavior: -delayed fills -nonadherence -pharmacy switching -financial anxiety and growing distrust in the benefit experience. At this point, members don’t just want “pricing transparency.” They want trusted guidance. And importantly: They don’t trust most existing tools enough to make important medication decisions. That’s the gap in the market. The industry has spent years assuming: “If consumers had pricing data, they would optimize.” But most consumers: -don’t want to become pharmacy experts, -don’t understand formularies, -and don’t trust generic coupon apps to guide clinically important decisions. Pharmacy navigators don't simply provide more pricing data. We help our clients understand: -when affordability changes behavior, -which members are most at risk, -and how to deliver trusted, personalized, clinically credible guidance before cost becomes abandonment. That is where the market is headed. #PharmacyBenefits #PBM #HealthcareInnovation #EmployeeBenefits #DigitalHealth #BenefitsStrategy #HealthcareCosts #RxBenefits #PharmacyNavigation #PatientEngagement #BehavioralEconomics #SelfInsured #HRLeadership #HealthcareTransformation #Pharmacy #HealthBenefits Scripta Insights Ferrin Williams, PharmD MBA Ashley Moyer Thom Stambaugh https://lnkd.in/ekSJbwE8
Agree…the market is finally moving beyond rebate transparency alone. Real-time navigation to the lowest net cost across the “full medicine cabinet,” while aligning clinical and financial decision-making at the member level, is huge. And DTC healthcare is moving quickly as consumers increasingly compare cash-pay options, digital pharmacies, telehealth platforms, and manufacturer programs. Consumers need help navigating the growing complexity. The organizations that can simplify and orchestrate all of those channels into a seamless member experience will have a major advantage.
Andrew Serio
5d
Great de-bunking of the "If Price is Transparent patients will shop " theoy of the 2010s. Good point on Navigation ( i.e. 100% patient Drug Adherence to prescriptions ordered by MD and counseled on by pharmacist). I would add to Navigation, Comparative Effectiveness Researsh ( C.E.R.) formulary ( See TruDataRx) because Patient Outcome, per episode of PCP MD care is the late 2020s focus of Cost Containment; not Best Price in Large self-insured Groups. Employer on-site clinics with PCP MD or DO, having a pharmacy on or near-site, have 100% patient Medical Compliance and Drug Adherence, per episode of care and thus have 3-4% Annual Plan Send since 2023 instead of 7-8%. Vertical Integrated Care; PCP-centric; 2027-2030 is the New Direction in ESI self-insurance.
#FACTS
Hit the nail on the head! Our clinical drug fit tool recognizes that exact same price point where basic necessity will outweigh paying for that prescription almost every time.